Description: Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
Home Page: www.atreca.com
BCEL Technical Analysis
835 Industrial Road
South San Francisco,
CA
94070
United States
Phone:
650 595 2595
Officers
| Name | Title |
|---|---|
| Mr. John A. Orwin | Pres, CEO & Director |
| Dr. Tito A. Serafini Ph.D. | Founder, Chief Strategy Officer & Director |
| Mr. Herbert C. Cross | Chief Financial Officer |
| Dr. Yann Chong Tan | Chief Technologist |
| Dr. Stephen Gould Ph.D. | Chief Scientific Officer |
| Ms. Courtney J. Phillips J.D. | Gen. Counsel & Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4018 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 91 |